Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia

This study has been completed.
Information provided by:
Memorial Sloan Kettering Cancer Center. Identifier:
First received: January 28, 2000
Last updated: January 17, 2013
Last verified: January 2013

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of sodium salicylate in treating patients who have advanced myelodysplastic syndrome , acute myelogenous leukemia or chronic lymphocytic leukemia.

Condition Intervention Phase
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Drug: sodium salicylate
Phase 1

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of Salicylate for Adult Patients With Advanced Myelodysplastic Disorders or Acute Myelogenous Leukemia

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center.:

Study Start Date: August 1999
Primary Completion Date: September 2004 (Final data collection date for primary outcome measure)
Detailed Description:


  • Evaluate the safety, toxicity, and pharmacokinetics of sodium salicylate in patients with advanced myelodysplastic syndrome; newly diagnosed, relapsed, or refractory acute myelogenous leukemia; or relapsed or refractory chronic lymphocytic leukemia.
  • Define biologic characteristics that influence the likelihood of a clinical response to this drug in this patient population.

OUTLINE: Patients receive oral sodium salicylate twice a day. Intrapatient dose escalation or de-escalation is permitted. Treatment continues for up to 6 weeks in the absence of unacceptable toxicity or disease progression. Responding patients may continue to receive sodium salicylate beyond the 6-week period.

Patients with acute myelogenous leukemia are followed until the end of therapy. Patients with myelodysplastic syndrome are followed until death or progression to leukemia.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 1 year.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Relapsed or refractory acute myelogenous leukemia OR
  • Elderly patients with newly diagnosed acute myelogenous leukemia not eligible for standard therapy OR
  • "High-risk" myelodysplastic syndrome, including:

    • Refractory anemia with excess blasts
    • Refractory anemia with excess blasts in transformation
    • Chronic myelomonocytic leukemia OR
  • Relapsed or refractory chronic lymphocytic leukemia
  • Not eligible for transplant protocols at MSKCC or refuses transplant
  • Not eligible for a higher priority protocol (e.g., bone marrow transplantation)



  • Over 18

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • Platelet count at least 25,000/mm^3


  • Bilirubin no greater than 2.0 mg/dL
  • Transaminase levels less than 3 times upper limit of normal
  • PT no greater than 14 seconds
  • PTT no greater than 34.6 seconds


  • Creatinine no greater than 2.0 mg/dL OR
  • Creatinine clearance greater than 60 mL/min


  • Not pregnant or nursing
  • No history of abnormal bleeding or unexplained bleeding disorders
  • No history of peptic ulcer disease
  • No salicylate allergy
  • No other concurrent active malignancy
  • No other concurrent illness that would preclude study assessment to a significant degree


Biologic therapy:

  • See Disease Characteristics


  • Not specified

Endocrine therapy:

  • Not specified


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00004245

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center.
Study Chair: Virginia Klimek, MD Memorial Sloan Kettering Cancer Center.
  More Information

Additional Information:
Publications: Identifier: NCT00004245     History of Changes
Other Study ID Numbers: 99-057, P30CA008748, MSKCC-99057, NCI-G99-1661
Study First Received: January 28, 2000
Last Updated: January 17, 2013
Health Authority: United States: Federal Government

Keywords provided by Memorial Sloan Kettering Cancer Center.:
recurrent adult acute myeloid leukemia
refractory chronic lymphocytic leukemia
untreated adult acute myeloid leukemia
refractory anemia with excess blasts
refractory anemia with excess blasts in transformation
chronic myelomonocytic leukemia
previously treated myelodysplastic syndromes
atypical chronic myeloid leukemia, BCR-ABL1 negative
myelodysplastic/myeloproliferative neoplasm, unclassifiable
adult acute myeloid leukemia with t(8;21)(q22;q22)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with t(15;17)(q22;q12)

Additional relevant MeSH terms:
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Leukemia, Myeloid
Neoplasms by Histologic Type
Precancerous Conditions
Salicylsalicylic acid
Sodium Salicylate
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on March 03, 2015